Zevra Therapeutics (ZVRA) Q4 2024 earnings summary

Executive summary

• Achieved FDA approval and commercial launch of Miplyffa for Niemann-Pick disease type C (NPC), marking transition to a commercial-stage company.

• Received 109 patient enrollment forms for Miplyffa in Q4, converting all active U.S. expanded access program (EAP) participants.

• Initiated European regulatory strategy, targeting a marketing authorization application in the second half of 2025.

• OLPRUVA launch for urea cycle disorders (UCDs) continued, with refined strategy to target adult onset population and 76% market access.

• Entered agreement to sell Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million in early 2025.

Financial highlights

• FY 2024 net revenue was $23.6M; Q4 2024 net revenue was $12.0M, driven by Miplyffa and OLPRUVA sales.

• FY 2024 net loss was $105.5M ($2.28/share) vs. $46M ($1.30/share) in 2023; Q4 net loss was $35.7M ($0.67/share) vs. $19.6M ($0.51/share) in Q4 2023.

• FY 2024 operating expenses were $97M, including $14.9M non-cash stock compensation and $2.7M severance.

• Cash, cash equivalents, and investments at year-end were $75.5M; PRV sale expected to add $148.3M net proceeds.

• Q4 2024 product revenue: $10.1M from Miplyffa, $0.1M from OLPRUVA, $1.1M from French EAP, $0.7M in royalties/other.

Outlook and guidance

• Pro forma cash after $150M PRV sale expected to be $223.8M; cash runway extends into 2029, excluding PRV proceeds.

• Focus for 2025: grow Miplyffa enrollments, expand OLPRUVA adoption, invest in pipeline, and execute European regulatory strategy.